Error in Text
- PMID: 32910135
- PMCID: PMC7489867
- DOI: 10.1001/jamaophthalmol.2020.3537
Error in Text
Erratum for
-
Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial.JAMA Ophthalmol. 2020 Sep 1;138(9):964-972. doi: 10.1001/jamaophthalmol.2020.2699. JAMA Ophthalmol. 2020. PMID: 32729897 Free PMC article. Clinical Trial.
References
-
- Khanani AM, Patel SS, Ferrone PJ, et al. Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY Phase 2 Randomized Clinical Trial. JAMA Ophthalmol. Published online July 30, 2020. doi: 10.1001/jamaophthalmol.2020.2699 - DOI - PMC - PubMed
